» Articles » PMID: 33897439

Effects of Hydroxylated Mephedrone Metabolites on Monoamine Transporter Activity

Overview
Journal Front Pharmacol
Date 2021 Apr 26
PMID 33897439
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Mephedrone is a largely abused psychostimulant. It elicits the release of monoamines via the high affinity transporters for dopamine (DAT), norepinephrine (NET) and serotonin (SERT). Stereoselective metabolic reactions are involved in the inactivation and the elimination of its chemical structure. However, during these processes, several structures are generated and some of them have been reported to be still pharmacologically active. In this study 1) we have newly synthetized several putative mephedrone metabolites, 2) compared their activity at monoamine transporters, 3) generated quantitative structure activity relationships, and 4) exploited the chemical structure of the putative metabolites to screen a urine sample from a drug user and dissect mephedrone metabolism. We have found that most of the tested metabolites are weak inhibitors of monoamine transporters and that all of them are more potent at DAT and NET in comparison to SERT. The only exception is represented by the COOH-metabolite which shows no pharmacological activity at all three monoamine transporters. The enantioselectivity of mephedrone and its metabolites is present mainly at SERT, with only minor effects at DAT and NET being introduced when the β-keto group is reduced to an OH-group. Importantly, while at DAT the putative metabolites did not show changes in inhibitory potencies, but rather changes in their substrate/blocker profile, at SERT they showed mainly changes in inhibitory potencies. Molecular modeling suggests that the hydrophobic nature of a specific SERT subpocket may be involved in such loss of affinity. Finally, the assessment of the putative metabolites in one urine sample of mephedrone user displayed two previously uncharacterized metabolites, 4-COOH-nor-mephedrone (4-COOH-MC) and dihydro-4- nor-mephedrone (dihydro-4-MC). These results confirm and expand previous studies highlighting the importance of the stereochemistry in the pharmacodynamics of phase-1 metabolites of mephedrone, established their structure-activity relationships at DAT, NET and SERT and pave the way for a systematic dissection of mephedrone metabolic routes. Given the number of structures found having residual and modified pharmacological profiles, these findings may help in understanding the complex subjective effects of administered mephedrone. Moreover, the dissection of mephedrone metabolic routes may help in developing new therapies for treating psychostimulants acute intoxications.

Citing Articles

Development and validation of an automated microfluidic perfusion platform for parallelized screening of compounds in vitro.

Brugnoli F, Holy M, Niello M, Maier J, Hanreich M, Menzel M Basic Clin Pharmacol Toxicol. 2023; 133(5):535-547.

PMID: 37658634 PMC: 10952622. DOI: 10.1111/bcpt.13940.


Persistent binding at dopamine transporters determines sustained psychostimulant effects.

Niello M, Sideromenos S, Gradisch R, O Shea R, Schwazer J, Maier J Proc Natl Acad Sci U S A. 2023; 120(6):e2114204120.

PMID: 36730201 PMC: 9963675. DOI: 10.1073/pnas.2114204120.


4-Isobutylmethcathinone-A Novel Synthetic Cathinone with High In Vitro Cytotoxicity and Strong Receptor Binding Preference of Enantiomers.

Paskan M, Rimpelova S, Pavlickova V, Spalovska D, Setnicka V, Kuchar M Pharmaceuticals (Basel). 2022; 15(12).

PMID: 36558946 PMC: 9780888. DOI: 10.3390/ph15121495.


Stereoselectivity in the Membrane Transport of Phenylethylamine Derivatives by Human Monoamine Transporters and Organic Cation Transporters 1, 2, and 3.

Gebauer L, Rafehi M, Brockmoller J Biomolecules. 2022; 12(10).

PMID: 36291716 PMC: 9599461. DOI: 10.3390/biom12101507.


A Novel and Selective Dopamine Transporter Inhibitor, -MK-26, Promotes Hippocampal Synaptic Plasticity and Restores Effort-Related Motivational Dysfunctions.

Kouhnavardi S, Ecevitoglu A, Dragacevic V, Sanna F, Arias-Sandoval E, Kalaba P Biomolecules. 2022; 12(7).

PMID: 35883437 PMC: 9312958. DOI: 10.3390/biom12070881.


References
1.
Ilic M, Holy M, Jaentsch K, Liechti M, Lubec G, Baumann M . Cell-Based Radiotracer Binding and Uptake Inhibition Assays: A Comparison of Methods to Assess the Potency of Drugs That Target Monoamine Transporters. Front Pharmacol. 2020; 11:673. PMC: 7248194. DOI: 10.3389/fphar.2020.00673. View

2.
Maier J, Mayer F, Luethi D, Holy M, Jantsch K, Reither H . The psychostimulant (±)-cis-4,4'-dimethylaminorex (4,4'-DMAR) interacts with human plasmalemmal and vesicular monoamine transporters. Neuropharmacology. 2018; 138:282-291. DOI: 10.1016/j.neuropharm.2018.06.018. View

3.
Reith M, Blough B, Hong W, Jones K, Schmitt K, Baumann M . Behavioral, biological, and chemical perspectives on atypical agents targeting the dopamine transporter. Drug Alcohol Depend. 2014; 147:1-19. PMC: 4297708. DOI: 10.1016/j.drugalcdep.2014.12.005. View

4.
Sakloth F, Kolanos R, Mosier P, Bonano J, Banks M, Partilla J . Steric parameters, molecular modeling and hydropathic interaction analysis of the pharmacology of para-substituted methcathinone analogues. Br J Pharmacol. 2014; 172(9):2210-8. PMC: 4403088. DOI: 10.1111/bph.13043. View

5.
Ordak M, Nasierowski T, Muszynska E . The growing problem of mephedrone use in Warsaw, Poland, 2010-18. Lancet Psychiatry. 2018; 5(10):787. DOI: 10.1016/S2215-0366(18)30305-5. View